글로벌 COVID-19 진단 시장 – 2029년까지의 산업 동향 및 예측

 COVID-19 진단 시장 분석 및 규모

질병통제예방센터(CDC)는 COVID-19를 유발하는 바이러스인 SARS-CoV-2를 식별하기 위한 두 가지 실험실 검사를 개발했습니다. 호흡기 검체에서 SARS-CoV-2를 검출하는 CDC 2019-신종 코로나바이러스(2019-nCoV) 실시간 RT-PCR 진단 패널은 COVID-19 진단을 위해 배포된 최초의 검사였으며 2020년 2월에 출시되었습니다. CDC는 2020년 7월에 공중 보건 실험실에서 단일 반응 웰에서 세 가지 검사를 실행할 수 있는 CDC 인플루엔자 SARS-CoV-2(Flu SC2) 멀티플렉스 검사를 출시했습니다. Flu SC2 멀티플렉스는 검사 시약을 덜 사용하고 처리량이 더 높으며 환자 검체에서 SARS-CoV-2, 인플루엔자 A 및 인플루엔자 B 핵산의 존재에 대한 정확한 결과를 제공합니다.

Data Bridge Market Research는 2021년에 467.6억 달러였던 COVID-19 진단 시장이 2029년까지 865.5억 달러에 도달할 것으로 분석했으며, 2022년부터 2029년까지의 예측 기간 동안 8.00%의 CAGR을 기록할 것으로 예상합니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

COVID-19 진단 시장 범위 및 세분화  

Market Definition

The novel coronavirus is a single-stranded RNA coronavirus that resembles existing SARS-CoV. As this spreads by close contact with an infected individual and is largely spread through respiratory droplets produced by coughing and sneezing. Coronavirus, which is now a global epidemic, was first discovered in the Chinese area of Wuhan. It is also known as coronavirus illness or COVID-19. RT-PCR, isothermal nucleic acid amplification, antibody detection, and other technologies are utilised in testing kits for the COVID-19 test, which is used to identify the SARS-CoV-2 virus. Serological tests are employed for population surveillance, diagnosis, and the identification of antibodies.

Global COVID-19 Diagnostics Market Dynamics

Drivers

•        Need for test kits in hospitals is a driver

The need for coronavirus test kits has expanded along with the coronavirus's widespread. With the aid of test kits, coronavirus identification has become more crucial than ever in order to control the infection's spread and boost the market expansion. Only specialised labs that are licenced to conduct the tests included in this kit, which are of the serology and molecular types. As the kits are based on techniques including real-time polymerase chain reactions, IgM ELISA tests, and microneutralization assays, samples are taken from the nose, sputum test, blood sample, throat swab, and nasal aspirate for testing. The demand for the industry is growing as a result of the global coronavirus outbreak.  As the number of patients in hospitals is increasing rapidly, the need for test kits in hospitals to diagnose the patients with symptoms is also increasing which is further drive the market growth.

•        Technological advancements in COVID-19 rapid testing

Vendors created a variety of innovative rapid testing kits, including cups, cards, and smart test kits. Saliva samples were employed in painless quick testing kits. Additionally, test kits with quicker findings were released on the market. Rapid testing is preferred over other COVID-19 testing kits as a result of these developments. For instance, Meril Diagnostics, an international medical firm with operations in India, produces the non-prescription CoviFind COVID-19 Rapid Antigen Self-Test, which is available and has received approval from the Indian Council of Medical Research (ICMR) for routine usage in India. The introduction of novel and innovative diagnostic tests, such as immunoenzymatic serological tests, rapid antigen tests, and RT PCR-based molecular tests, is expected to drive industry demand.

Opportunities

• Rising number of COVID-19 patients

With the rapidly increasing number of COVID-19 patients worldwide, healthcare professionals require a consistent supply of diagnostic kits, which is expected to have a significant impact on the COVID-19 diagnostics market from 2022 to 2029. The growing number of suspected cases and the need to ensure that test results are correct which has resulted in an increase in demand for more kits, as well as increased safety concerns and the need to diagnose and isolate infected persons, which are expected to boost market growth.

Restraints/Challenges

• Lack of knowledge regarding COVID-19

Lack of knowledge regarding COVID-19 and its symptoms, ability to increase in certain developing regions among professionals will obstruct the market's growth rate. Time required for result is more than 24 hours which is bit longer and will act as a restraint, and further challenge the growth of the COVID-19 Diagnostics market in the forecast period mentioned above. The increased number of false-positive and false-negative results is one of the main drawbacks of fast testing. A set of COVID-19 test kits contained instances of findings that were both falsely positive and falsely negative. When verified with alternate COVID-19 testing, individuals with COVID-19 symptoms both tested negative and positive. These incidents caused the use of COVID-19 fast test kits to decline in some countries.

This COVID-19 diagnostics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the COVID-19 diagnostics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on the COVID-19 Diagnostics Market

COVID-19 had a positive impact on the market, by finding the sick person and person-to-person transmission, the testing significantly contributes to controlling and mitigating the pandemic. One of the most frequently used COVID-19 tests worldwide is rapid antigen testing. Results from this diagnosis, which quantifies the amount of viral protein, can be obtained in within 15 minutes. However, with time, more people started using fast diagnostics kits, and vendors also started making highly sensitive COVID-19 rapid test kits.

Recent developments

• In July 2021, Abbott launched the PanbioTM COVID-19 antigen self-test in India to expand its quick diagnostics offering to meet screening requirements at home, work, and clinics.
• In March 2021 Roche Diagnostics announced the permission for Emergency Use Authorization (EUA) from the United States Food and Drug Administration (FDA) for the COVID-19 rapid antigen test, which is intended for use by healthcare professionals in point-of-care situations with COVID-19 patients.

Global COVID-19 Diagnostics Market Scope

The COVID-19 diagnostics market is segmented on the basis of test type, product, technology, sample type, setting and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Test Type

• Molecular Assays
• Serologic Immunoassays
• Ancillary Diagnostic Tests

 Product

• Polymerase Chain Reaction Kits
• Point-of-care (POC) tests Kits
• Immunoassay
• Instruments
• Reagent and kits

 Technology

• Polymerase Chain Reaction (PCR)
• Enzyme Linked Immunosorbent Assay (ELISA)
• Lateral Flow Immunoassay (LFIA)
• Others

Sample Type

• Oropharyngeal and Nasopharyngeal Swabs
• Nasal Swabs
• Blood
• Others

 Setting

• Lab based
• Point of Care

 End User

• Hospitals
• Public Health Labs
• Private or Commercial Labs
• Urgent care clinics
• Physician Labs

COVID-19 Diagnostics Market Regional Analysis/Insights

The COVID-19 diagnostics market is analysed and market size insights and trends are provided by country, test type, product, technology, sample type, setting and end user as referenced above.

The countries covered in the COVID-19 diagnostics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the COVID-19 diagnostics market due to the well-established healthcare system and the presence of numerous existing pharma companies in this particular region.

아시아 태평양 지역은 코로나바이러스 확진자가 증가하고 여러 업계 참여자가 있는 덕분에 2022년부터 2029년까지 예측 기간 동안 가장 높은 성장률을 기록할 것으로 예상됩니다.

보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 다운스트림 및 업스트림 가치 사슬 분석, 기술 트렌드 및 포터의 5가지 힘 분석, 사례 연구와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 몇 가지 포인터입니다. 또한 글로벌 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 국내 관세 및 무역 경로의 영향은 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.

의료 인프라 성장 설치 기반 및 신기술 침투

COVID-19 진단 시장은 또한 모든 국가의 자본 장비에 대한 의료 지출 증가, COVID-19 진단 시장을 위한 다양한 종류의 제품 설치 기반, 수명선 곡선을 사용하는 기술의 영향, 의료 규제 시나리오의 변화 및 COVID-19 진단 시장에 미치는 영향에 대한 자세한 시장 분석을 제공합니다. 이 데이터는 2010-2020년의 과거 기간에 대한 것입니다.

경쟁 환경 및 COVID-19 진단 시장 점유율 분석

COVID-19 진단 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 프로그램 우위가 있습니다. 위에 제공된 데이터 포인트는 COVID-19 진단 시장과 관련된 회사의 초점에만 관련이 있습니다.

COVID-19 진단 시장에서 활동하는 주요 업체는 다음과 같습니다.

• QIAGEN(독일)
• F.호프만-라로슈 유한회사(스위스)
• Seegene Inc (한국)
• 솔젠트 주식회사(한국)
• 쿠레티스(독일)
• 쿠르보산업 주식회사(일본)
• 데벡스(미국)
• Thermo Fisher Scientific Inc(미국)
• Mylab Discovery Solutions Pvt. Ltd(인도)
• 애벗(미국)
• Getein Biotech, Inc(중국)
• Biomaxima SA(폴란드)
• CTK 바이오텍 주식회사 (미국)
• 질병통제예방센터(CDC)(미국)
• BGI(중국)
• 루미넥스 코퍼레이션(미국)
• 아벨리노닷컴(미국)
• 퍼킨엘머 주식회사(미국)
• 다나허(미국)
• Thermo Fisher Scientific Inc. (미국)

SKU-55939